Leerink Partnrs Has Negative Outlook of RARE FY2024 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Research analysts at Leerink Partnrs reduced their FY2024 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a report released on Tuesday, November 5th. Leerink Partnrs analyst J. Schwartz now expects that the biopharmaceutical company will earn ($6.31) per share for the year, down from their previous forecast of ($6.27). The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($6.29) per share. Leerink Partnrs also issued estimates for Ultragenyx Pharmaceutical's Q4 2024 earnings at ($1.41) EPS, Q1 2025 earnings at ($1.47) EPS, Q2 2025 earnings at ($1.38) EPS, Q3 2025 earnings at ($1.33) EPS, Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($5.44) EPS and FY2026 earnings at ($2.42) EPS.

Several other equities research analysts have also commented on the company. Wells Fargo & Company upped their target price on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the company an "overweight" rating in a research report on Friday, August 2nd. HC Wainwright increased their price target on Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the stock a "buy" rating in a report on Wednesday. Royal Bank of Canada reiterated an "outperform" rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday. TD Cowen increased their price target on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Finally, The Goldman Sachs Group increased their price target on Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a "buy" rating in a report on Friday, August 2nd. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $86.69.

Ultragenyx Pharmaceutical Stock Down 0.1 %

Shares of Ultragenyx Pharmaceutical stock traded down $0.07 on Friday, hitting $50.36. 1,246,767 shares of the company's stock traded hands, compared to its average volume of 783,398. Ultragenyx Pharmaceutical has a one year low of $34.06 and a one year high of $60.37. The company has a fifty day moving average of $55.19 and a two-hundred day moving average of $48.12.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 197.73% and a negative net margin of 106.93%. The company had revenue of $139.49 million for the quarter, compared to analyst estimates of $135.28 million. During the same quarter in the prior year, the company earned ($2.23) EPS. The firm's revenue for the quarter was up 42.3% compared to the same quarter last year.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,465 shares of the stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the sale, the chief financial officer now directly owns 92,301 shares of the company's stock, valued at approximately $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CFO Howard Horn sold 7,465 shares of the stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the sale, the chief financial officer now directly owns 92,301 shares of the company's stock, valued at approximately $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the sale, the chief executive officer now directly owns 2,223,985 shares of the company's stock, valued at $124,209,562.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,556 shares of company stock valued at $1,515,967 over the last ninety days. 5.80% of the stock is currently owned by insiders.

Institutional Trading of Ultragenyx Pharmaceutical

A number of large investors have recently bought and sold shares of RARE. Allspring Global Investments Holdings LLC increased its position in Ultragenyx Pharmaceutical by 67.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 3,318 shares of the biopharmaceutical company's stock worth $155,000 after buying an additional 1,339 shares during the last quarter. Capstone Investment Advisors LLC purchased a new stake in Ultragenyx Pharmaceutical in the first quarter worth $227,000. GSA Capital Partners LLP purchased a new stake in Ultragenyx Pharmaceutical in the first quarter worth $493,000. Duality Advisers LP increased its position in Ultragenyx Pharmaceutical by 1.5% in the first quarter. Duality Advisers LP now owns 39,977 shares of the biopharmaceutical company's stock worth $1,867,000 after buying an additional 606 shares during the last quarter. Finally, Swiss National Bank increased its position in Ultragenyx Pharmaceutical by 3.0% in the first quarter. Swiss National Bank now owns 145,852 shares of the biopharmaceutical company's stock worth $6,810,000 after buying an additional 4,300 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.